vs

Side-by-side financial comparison of IMMERSION CORP (IMMR) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $372.9M, roughly 1.7× IMMERSION CORP). Royalty Pharma plc runs the higher net margin — 34.4% vs -4.6%, a 39.0% gap on every dollar of revenue. On growth, IMMERSION CORP posted the faster year-over-year revenue change (750.4% vs 4.8%). Over the past eight quarters, IMMERSION CORP's revenue compounded faster (537.9% CAGR vs 4.6%).

Immersion Corporation is an Aventura, Florida based developer and licensor of touch feedback technology, also known as haptic technology. Immersion Corporation has been accused of being a patent troll. Founded in 1993 by Louis Rosenberg, it is currently headed by lawyer Francis Jose, who serves as both chief executive officer and general counsel.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

IMMR vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.7× larger
RPRX
$622.0M
$372.9M
IMMR
Growing faster (revenue YoY)
IMMR
IMMR
+745.6% gap
IMMR
750.4%
4.8%
RPRX
Higher net margin
RPRX
RPRX
39.0% more per $
RPRX
34.4%
-4.6%
IMMR
Faster 2-yr revenue CAGR
IMMR
IMMR
Annualised
IMMR
537.9%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IMMR
IMMR
RPRX
RPRX
Revenue
$372.9M
$622.0M
Net Profit
$-17.0M
$214.2M
Gross Margin
Operating Margin
-2.8%
62.4%
Net Margin
-4.6%
34.4%
Revenue YoY
750.4%
4.8%
Net Profit YoY
-191.3%
2.9%
EPS (diluted)
$-0.57
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMMR
IMMR
RPRX
RPRX
Q4 25
$622.0M
Q3 25
$609.3M
Q2 25
$372.9M
$578.7M
Q1 25
$471.3M
$568.2M
Q4 24
$616.2M
$593.6M
Q3 24
$564.7M
Q2 24
$95.5M
$537.3M
Q1 24
$43.8M
$568.0M
Net Profit
IMMR
IMMR
RPRX
RPRX
Q4 25
$214.2M
Q3 25
$288.2M
Q2 25
$-17.0M
$30.2M
Q1 25
$24.1M
$238.3M
Q4 24
$30.8M
$208.2M
Q3 24
$544.0M
Q2 24
$26.4M
$102.0M
Q1 24
$18.7M
$4.8M
Operating Margin
IMMR
IMMR
RPRX
RPRX
Q4 25
62.4%
Q3 25
70.1%
Q2 25
-2.8%
36.3%
Q1 25
7.5%
94.0%
Q4 24
11.4%
60.9%
Q3 24
Q2 24
23.7%
50.2%
Q1 24
37.9%
-13.0%
Net Margin
IMMR
IMMR
RPRX
RPRX
Q4 25
34.4%
Q3 25
47.3%
Q2 25
-4.6%
5.2%
Q1 25
5.1%
41.9%
Q4 24
5.0%
35.1%
Q3 24
96.3%
Q2 24
27.7%
19.0%
Q1 24
42.5%
0.8%
EPS (diluted)
IMMR
IMMR
RPRX
RPRX
Q4 25
$0.49
Q3 25
$0.67
Q2 25
$-0.57
$0.07
Q1 25
$0.73
$0.55
Q4 24
$0.93
$0.46
Q3 24
$1.21
Q2 24
$0.81
$0.23
Q1 24
$0.59
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMMR
IMMR
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$161.4M
$618.7M
Total DebtLower is stronger
$103.1M
$9.0B
Stockholders' EquityBook value
$298.1M
$9.7B
Total Assets
$1.1B
$19.6B
Debt / EquityLower = less leverage
0.35×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMMR
IMMR
RPRX
RPRX
Q4 25
$618.7M
Q3 25
$938.9M
Q2 25
$161.4M
$631.9M
Q1 25
$153.9M
$1.1B
Q4 24
$159.3M
$929.0M
Q3 24
$950.1M
Q2 24
$133.4M
$1.8B
Q1 24
$179.1M
$843.0M
Total Debt
IMMR
IMMR
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$103.1M
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
IMMR
IMMR
RPRX
RPRX
Q4 25
$9.7B
Q3 25
$9.6B
Q2 25
$298.1M
$9.5B
Q1 25
$317.9M
$9.8B
Q4 24
$305.5M
$10.3B
Q3 24
$10.3B
Q2 24
$273.4M
$9.8B
Q1 24
$201.5M
$9.9B
Total Assets
IMMR
IMMR
RPRX
RPRX
Q4 25
$19.6B
Q3 25
$19.3B
Q2 25
$1.1B
$18.3B
Q1 25
$1.4B
$17.6B
Q4 24
$1.4B
$18.2B
Q3 24
$18.0B
Q2 24
$1.2B
$17.7B
Q1 24
$244.7M
$16.1B
Debt / Equity
IMMR
IMMR
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.35×
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMMR
IMMR
RPRX
RPRX
Operating Cash FlowLast quarter
$827.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMMR
IMMR
RPRX
RPRX
Q4 25
$827.1M
Q3 25
$702.6M
Q2 25
$364.0M
Q1 25
$-43.7M
$596.1M
Q4 24
$742.5M
Q3 24
$703.6M
Q2 24
$-85.9M
$658.2M
Q1 24
$29.9M
$664.6M
Free Cash Flow
IMMR
IMMR
RPRX
RPRX
Q4 25
Q3 25
Q2 25
Q1 25
$-46.2M
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
IMMR
IMMR
RPRX
RPRX
Q4 25
Q3 25
Q2 25
Q1 25
-9.8%
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
IMMR
IMMR
RPRX
RPRX
Q4 25
Q3 25
Q2 25
Q1 25
0.5%
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
IMMR
IMMR
RPRX
RPRX
Q4 25
3.86×
Q3 25
2.44×
Q2 25
12.06×
Q1 25
-1.82×
2.50×
Q4 24
3.57×
Q3 24
1.29×
Q2 24
-3.25×
6.45×
Q1 24
1.60×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMMR
IMMR

Course Material Sale$150.9M40%
General Merchandise Sale$138.0M37%
Rental Services$51.8M14%
Services And Other Revenue$25.6M7%
Per Unit Royalties$1.8M0%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons